Location: Solmed Polyclinic (Zagreb), SB Medico (Rijeka)
Study Drug: Biological therapy involving already registered drugs from the IL-23 antagonist and IL-1 antagonist groups, which will be administered alone (monotherapy) or in combination with an experimental drug from the anti-a4B7 mAb group.
Main Inclusion Criteria: Adult patients diagnosed with Crohn’s disease or ulcerative colitis who, despite treatment with any medication, have moderately severe or severe symptoms of the disease.
Status: In preparation
Start of patient enrollment: January 2025.
